4
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Chlorine dioxide is a more potent antiviral agent against SARS-CoV-2 than sodium hypochlorite

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A new coronavirus (SARS-CoV-2) abruptly emerged in Wuhan, China in 2019 and rapidly spread globally to cause the COVID-19 pandemic. In this study, we examined the anti-SARS-CoV-2 activity of the potent disinfectant Cleverin, the major disinfecting component of which is chlorine dioxide (ClO 2) and the results were compared with that of sodium hypochlorite in the presence or absence of 0.5% or 1.0% fetal bovine serum (FBS). When SARS-CoV-2 viruses were treated with 0.8 ppm ClO 2 or sodium hypochlorite, viral titre was decreased only by 1 log TCID 50/mL in 3 min. However, the viral titre was decreased by more than 4 logs TCID 50/mL when treated with 80 ppm of each chemical for 10 sec regardless of presence or absence of FBS. It should be emphasized that treatment with 24 ppm of ClO 2 inactivated more than 99.99% SARS-CoV-2 within 10 sec or 99.99% SARS-CoV-2 in 1 min in the presence of 0.5% or 1.0% FBS, respectively. In contrast, 24 ppm of sodium hypochlorite was able to inactivate only 99% or 90% SARS-CoV-2 in 3 min under similar conditions. Notably, except ClO 2 the other components of Cleverin such as sodium chlorite, decaglycerol monolaurate and silicone showed no significant antiviral activity. Altogether, the results strongly suggest that although ClO 2 and sodium hypochlorite are strong antiviral agents in absence of organic matters but in presence of organic matters ClO 2 is a more potent antiviral agent against SARS-CoV-2 than sodium hypochlorite.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          A Novel Coronavirus from Patients with Pneumonia in China, 2019

          Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

            How SARS-CoV-2 binds to human cells Scientists are racing to learn the secrets of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), which is the cause of the pandemic disease COVID-19. The first step in viral entry is the binding of the viral trimeric spike protein to the human receptor angiotensin-converting enzyme 2 (ACE2). Yan et al. present the structure of human ACE2 in complex with a membrane protein that it chaperones, B0AT1. In the context of this complex, ACE2 is a dimer. A further structure shows how the receptor binding domain of SARS-CoV-2 interacts with ACE2 and suggests that it is possible that two trimeric spike proteins bind to an ACE2 dimer. The structures provide a basis for the development of therapeutics targeting this crucial interaction. Science, this issue p. 1444
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses

              An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18-55 years of age. Two doses of 1-50 μg of BNT162b1 elicited robust CD4+ and CD8+ T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-μg dose) to 3.5-fold (50-μg dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (TH1)-skewed T cell immune responses with RBD-specific CD8+ and CD4+ T cell expansion. Interferon-γ was produced by a large fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
                Bookmark

                Author and article information

                Journal
                J Hosp Infect
                J Hosp Infect
                The Journal of Hospital Infection
                The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society.
                0195-6701
                1532-2939
                15 September 2021
                15 September 2021
                Affiliations
                [1 ]Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-58, Rinkuourai-kita, Izumisano, Osaka 598-8531, Japan
                [2 ]Asian Health Science Research Institute, Osaka Prefecture University, 1-58, Rinkuourai-kita, Izumisano, Osaka 598-8531, Japan
                [3 ]Osaka International Research Center for Infectious Diseases, Osaka Prefecture University, 1-58, Rinkuourai-kita, Izumisano, Osaka 598-8531, Japan
                [4 ]Research and Development Center, Taiko Pharmaceutical Co. Ltd., 1-2-1, Hikaridai, Seika-cho, Soraku-gun, Kyoto, 619-0237, Japan
                Author notes
                []Corresponding author: Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-58, Rinku ourai-kita, Izumisano, Osaka 598-8531, Japan. Tel & Fax: +81-72-463-5653. JHI-v210904
                Article
                S0195-6701(21)00320-0
                10.1016/j.jhin.2021.09.006
                8442261
                34536532
                d113ca69-8d8f-4aaa-a462-a72bbab3b396
                © 2021 The Author(s)

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 6 September 2021
                : 9 September 2021
                Categories
                Article

                Infectious disease & Microbiology
                chlorine dioxide,sodium hypochlorite,sars-cov-2
                Infectious disease & Microbiology
                chlorine dioxide, sodium hypochlorite, sars-cov-2

                Comments

                Comment on this article